Clinical Trial

Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 16, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This multicenter retrospective real-world study aims to evaluate the safety, efficacy and survival outcomes of neoadjuvant/induction immunotherapy in patients with non-small cell lung cancer (NSCLC). The study covers diverse treatment pathways, including surgery, definitive radiotherapy, and non-surgical strategies. It addresses gaps in existing trials by establishing a comprehensive cohort spanning neoadjuvant/induction therapy, perioperative management, and follow-up, providing real-world evidence to support treatment decisions in both operable and inoperable cases.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-07.
Trial Details
NCT Number NCT06926179
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions Lung Cancer (NSCLC), Neoadjuvant Immunotherapy, Radiotherapy, Lung Surgery
Enrollment 500 participants
Start Date 2024-12-01
Primary Completion 2026-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-16